Cost of cancer drugs not linked to clinical benefit, study finds

(By Maia Anderson for Becker’s Hospital Review)

The costs of dozens of cancer drugs were about 2.3 times higher in the U.S. than in Europe even though they had similar clinical benefits, according to a study cited by STAT.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.